TNF and glycogen storage disease VI: Development of novel approaches to overcome these limitations is becoming even more important, as recent evidence supports the advantage of earlier use of TNF-α inhibitors, before the failure of conventional DMARDs, and especially to use TNF inhibitors in combination with methotrexate as first-line therapy in patients with poor prognosis and signs for rapidly progressive disease [25].